Epizyme Inc. (EPZM)

12.12
NASDAQ : Health Technology
Prev Close 12.32
Day Low/High 12.09 / 12.50
52 Wk Low/High 5.14 / 18.70
Avg Volume 774.00K
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 1.12B
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Epizyme, Inc. To Present At 2015 Wedbush PacGrow Healthcare Conference

Epizyme, Inc. To Present At 2015 Wedbush PacGrow Healthcare Conference

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced its participation at the 2015 Wedbush PacGrow Healthcare Conference on...

Epizyme To Report Second Quarter 2015 Financial Results And Provide Corporate Update On August 6, 2015

Epizyme To Report Second Quarter 2015 Financial Results And Provide Corporate Update On August 6, 2015

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call and live audio webcast on Thursday, August...

Short Interest Moves 23.2% Higher For EPZM

Short Interest Moves 23.2% Higher For EPZM

The most recent short interest data has been released by the NASDAQ for the 07/15/2015 settlement date, which shows a 1,274,733 share increase in total short interest for Epizyme Inc. , to 6,771,087, an increase of 23.19% since 06/30/2015.

Use Options For a Chance To Buy EPZM at a 20% Discount

Use Options For a Chance To Buy EPZM at a 20% Discount

Looking back to 127 days ago, Epizyme Inc. priced a 6,000,000 share secondary stock offering at $20.75 per share.

Analysts' Actions -- Amazon, Hertz and Kraft Heinz

Analysts' Actions -- Amazon, Hertz and Kraft Heinz

Here are Monday's top research calls, including an upgrade of Amazon and new coverage of Kraft Heinz.

Epizyme Doses First Patient In Five-Arm Phase 2 Study For First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme Doses First Patient In Five-Arm Phase 2 Study For First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that it has dosed the first patient in the phase 2 trial of its lead clinical...

Epizyme Announces Extension Of Celgene Research Collaboration

Epizyme Announces Extension Of Celgene Research Collaboration

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced that it has amended and restated its agreement with Celgene Corporation to...

Strong On High Relative Volume: Epizyme (EPZM)

Strong On High Relative Volume: Epizyme (EPZM)

Trade-Ideas LLC identified Epizyme (EPZM) as a strong on high relative volume candidate

Today's Perilous Reversal Stock: Epizyme (EPZM)

Today's Perilous Reversal Stock: Epizyme (EPZM)

Trade-Ideas LLC identified Epizyme (EPZM) as a "perilous reversal" (up big yesterday but down big today) candidate

Market News: Apollo Education Group, Epizyme, Juno Therapeutics

Market News: Apollo Education Group, Epizyme, Juno Therapeutics

The stock markets in the United States rallied today after suffering a significant decline yesterday due to investors' concerns regarding the potential exit of Greece in the Eurozone. Sign up for o...

Celgene on My Shopping List for a Pullback

Celgene on My Shopping List for a Pullback

I have about 25% in cash; if the market falls 5-10%, I'm in.

Epizyme To Present Clinical Data From Ongoing Phase 1 Dose Escalation Trial Of Tazemetostat (EPZ-6438) At The European Cancer Congress

Epizyme To Present Clinical Data From Ongoing Phase 1 Dose Escalation Trial Of Tazemetostat (EPZ-6438) At The European Cancer Congress

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the phase 1 portion of its ongoing phase 1/2 study of...

Jim Cramer: Here Are Companies That Prove the Bears Wrong

Jim Cramer: Here Are Companies That Prove the Bears Wrong

Forget the Fed. Here are companies that are pushing the market higher for a variety of reasons.

Interesting EPZM Put And Call Options For February 2016

Interesting EPZM Put And Call Options For February 2016

Investors in Epizyme Inc. saw new options begin trading this week, for the February 2016 expiration.

Perilous Reversal Stock: Epizyme (EPZM)

Perilous Reversal Stock: Epizyme (EPZM)

Trade-Ideas LLC identified Epizyme (EPZM) as a "perilous reversal" (up big yesterday but down big today) candidate

Some Companies Keep Proving the Bears Wrong

As long as this keeps happening, don't stay away.

Market News: Cigna, Williams Companies, Epizyme

Market News: Cigna, Williams Companies, Epizyme

The stock markets in the United States rallied driven by investors' optimism regarding the debt negotiations in Europe and reports on mergers & acquisitions. Sign up for our free newsletter Pau...

Epizyme Announces Additional Positive Data From Ongoing Phase 1 Study Of Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme Announces Additional Positive Data From Ongoing Phase 1 Study Of Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today reported results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a...

Epizyme, Inc. To Present At Upcoming Events In June

Epizyme, Inc. To Present At Upcoming Events In June

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming events in June: ...

Short Interest Makes 17% Move For EPZM

Short Interest Makes 17% Move For EPZM

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, which shows a 577,366 share increase in total short interest for Epizyme Inc. , to 3,943,956, an increase of 17.15% since 04/30/2015.

Epizyme To Present At Upcoming Conferences In May

Epizyme To Present At Upcoming Conferences In May

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming conferences in May: ...

Epizyme Announces First Quarter 2015 Financial Results And Provides Corporate Update

Epizyme Announces First Quarter 2015 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today reported business highlights and operating and financial results for the...

Epizyme To Report First Quarter 2015 Financial Results And Provide Corporate Update On April 28, 2015

Epizyme To Report First Quarter 2015 Financial Results And Provide Corporate Update On April 28, 2015

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that it will host a conference call and live audio webcast on Tuesday,...

Epizyme Presents Preclinical Research Providing Deeper Understanding Of Multiple Cancer Targets

Epizyme Presents Preclinical Research Providing Deeper Understanding Of Multiple Cancer Targets

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the presentation of data on two epigenetic targets in its pioneering...

Epizyme To Present Updated Data From Ongoing Phase 1 Dose Escalation Trial Of EZH2 Inhibitor EPZ-6438 At International Conference On Malignant Lymphoma

Epizyme To Present Updated Data From Ongoing Phase 1 Dose Escalation Trial Of EZH2 Inhibitor EPZ-6438 At International Conference On Malignant Lymphoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that updated data from the Phase 1 portion of the ongoing Phase 1/2...

Epizyme Announces Closing Of Common Stock Offering

Epizyme Announces Closing Of Common Stock Offering

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten...

First Week of November 20th Options Trading For Epizyme (EPZM)

First Week of November 20th Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options become available this week, for the November 20th expiration.

Epizyme To Present Data On Preclinical Pipeline At The American Association For Cancer Research (AACR) Annual Meeting

Epizyme To Present Data On Preclinical Pipeline At The American Association For Cancer Research (AACR) Annual Meeting

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from its preclinical pipeline will be presented during the...

Trade-Ideas: Epizyme (EPZM) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Epizyme (EPZM) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Epizyme (EPZM) as a pre-market mover with heavy volume candidate

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 6,000,000 shares of its common stock...

TheStreet Quant Rating: D (Sell)